Aqumeldi Proveca Pharma Limited · Authorised · authorised 15 Nov 2023 · ATC C09AA02
Therapeutic indication (EMA)
Treatment of heart failure.
Active substance
Enalapril
- SFDA 25
- US FDA 26
- EMA 1
- Health Canada 39
- US price lines 6
- NHS prices 6
- WHO EML 2
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ENAPRIL 10 MG TAB | 10 mg | Tablet · Oral use | 30 Blister | SAR 44.40 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| KORANDIL | 20 mg | Tablet · Oral use | 10 Blister | SAR 14.75 | Generic · Prescription | REMEDICA | Valid |
| LAPRIL 10 mg tablet | 10 mg | Tablet · Oral use | 20 Blister | SAR 20.20 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| LAPRIL 20 MG TABLET | 20 mg | Tablet · Oral use | 20 Blister | SAR 33.15 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| LAPRIL 20MG TABLETS | 20 mg | Tablet · Oral use | 30 Blister | SAR 39.80 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| LAPRIL 5 mg tablet | 5 mg | Tablet · Oral use | 20 Blister | SAR 12.35 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| RENITEC | 5 mg | Tablet · Oral use | 28 Blister | SAR 35.15 | NCE · Prescription | ORGANON | Valid |
| RENITEC | 20 mg | Tablet · Oral use | 28 Blister | SAR 58.50 | NCE · Prescription | ORGANON | Valid |
| RENITEC | 10 mg | Tablet · Oral use | 28 Blister | SAR 45.20 | NCE · Prescription | ORGANON | Valid |
| ANGIOTEC 10MG TAB | 10 mg | Tablet · Oral use | 30 Blister | SAR 34.55 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Suspended · Not Marketed |
| ANGIOTEC 20MG TAB | 20 mg | Tablet · Oral use | 20 Blister | SAR 41.55 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Suspended · Not Marketed |
| ANGIOTEC 5MG TAB | 5 mg | Tablet · Oral use | 30 Blister | SAR 25.40 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Suspended · Not Marketed |
| ENAPRIL 20 MG TAB | 20 mg | Tablet · Oral use | 30 Blister | SAR 58.55 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| ENAPRIL 5 MG TAB | 5 mg | Tablet · Oral use | 30 Blister | SAR 26.20 | Generic · Prescription | SPIMACO ADDWAEIH | Withdrawn by MAH · Not Marketed |
| ESOPRESS 10MG TAB | 10 mg | Tablet · Oral use | 30 Blister | SAR 49.35 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| NARAPRIL 10MG TABLET | 10 mg | Tablet · Oral use | 28 Blister | SAR 33.55 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| NARAPRIL 20MG TABLET | 20 mg | Tablet · Oral use | 28 Blister | SAR 44.25 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| NARAPRIL 5MG TABLET | 5 mg | Tablet · Oral use | 28 Blister | SAR 19.80 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| RENITEC | 20 mg | Tablet · Oral use | 14 Blister | SAR 42.20 | NCE · Prescription | MERCK SHARP & DOHME | Withdrawn by MAH · Not Marketed |
| RIAPRIL | 10 mg | Tablet · Oral use | 30 Blister | SAR 39.95 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIAPRIL | 20 mg | Tablet · Oral use | 30 Blister | SAR 52.70 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIAPRIL | 5 mg | Tablet · Oral use | 30 Blister | SAR 23.60 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| VASOPRIL 10MG TABLET | 10 mg | Tablet · Oral use | 30 Blister | SAR 32.35 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Withdrawn by MAH · Not Marketed |
| VASOPRIL 20MG TABLET | 20 mg | Tablet · Oral use | 30 Blister | SAR 42.65 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Withdrawn by MAH · Not Marketed |
| VASOPRIL 5MG TABLET | 5 mg | Tablet · Oral use | 30 Blister | SAR 19.10 | Generic · Prescription | SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CARDIOMYOPATHY; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HYPERTENSION; SICKLE CELL DISEASE - ALBUMINURIA MANAGEMENT; SYSTEMIC LUPUS ERYTHEMATOSUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VASOTEC | 5MG; 10MG; 20MG; 2.5MG | tablet · oral | BAUSCH | Prescription | 24 Dec 1985 |
| ENALAPRIL MALEATE | 10MG; 20MG | tablet · oral | SANDOZ INC | Prescription | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | HERITAGE PHARMA | Prescription | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | SENORES PHARMS | Prescription | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG | tablet · oral | SANDOZ INC | Prescription | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | TARO | Prescription | 23 Jan 2001 |
| ENALAPRIL MALEATE | 5MG; 2.5MG; 10MG; 20MG | tablet · oral | AIPING PHARM INC | Prescription | 23 Mar 2001 |
| EPANED | 1MG/ML | solution · oral | AZURITY | Prescription | 20 Sep 2016 |
| ENALAPRIL MALEATE | 1MG/ML | solution · oral | BIONPHARMA | Prescription | 10 Aug 2021 |
| ENALAPRIL MALEATE | 1MG/ML | solution · oral | ANNORA PHARMA | Prescription | 24 Feb 2022 |
| ENALAPRIL MALEATE | 1MG/ML | solution · oral | ALKEM LABS LTD | Prescription | 30 Mar 2022 |
| ENALAPRIL MALEATE | 1MG/ML | solution · oral | AMNEAL | Prescription | 29 Jun 2022 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | PRINSTON INC | Prescription | 7 Jul 2022 |
| ENALAPRIL MALEATE | 1MG/ML | solution · oral | AUROBINDO PHARMA | Prescription | 8 Jan 2024 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | UNIQUE PHARM | Prescription | 19 Sep 2024 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | CHARTWELL RX | Discontinued | 22 Aug 2000 |
| ENALAPRIL MALEATE | 10MG; 20MG | tablet · oral | KRKA DD NOVO MESTO | Discontinued | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG | tablet · oral | KRKA DD NOVO MESTO | Discontinued | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | MYLAN | Discontinued | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | AUROBINDO PHARMA USA | Discontinued | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | IVAX SUB TEVA PHARMS | Discontinued | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | WATSON LABS | Discontinued | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | SUN PHARM INDS LTD | Discontinued | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | APOTHECON | Discontinued | 22 Aug 2000 |
| ENALAPRIL MALEATE | 2.5MG; 5MG; 10MG; 20MG | tablet · oral | REGCON HOLDINGS | Discontinued | 22 Aug 2000 |
1 more — full table
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ACT ENALAPRIL | 02291878 | 2 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ACT ENALAPRIL | 02291886 | 4 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ACT ENALAPRIL | 02291894 | 8 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| ACT ENALAPRIL | 02291908 | 16 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| APO-ENALAPRIL | 02019884 | 5 MG | TABLET · ORAL | APOTEX INC |
| APO-ENALAPRIL | 02019892 | 10 MG | TABLET · ORAL | APOTEX INC |
| APO-ENALAPRIL | 02019906 | 20 MG | TABLET · ORAL | APOTEX INC |
| APO-ENALAPRIL | 02020025 | 2.5 MG | TABLET · ORAL | APOTEX INC |
| ENALAPRIL | 02400650 | 2.5 MG | TABLET · ORAL | SANIS HEALTH INC |
| ENALAPRIL | 02400669 | 5 MG | TABLET · ORAL | SANIS HEALTH INC |
| ENALAPRIL | 02400677 | 10 MG | TABLET · ORAL | SANIS HEALTH INC |
| ENALAPRIL | 02400685 | 20 MG | TABLET · ORAL | SANIS HEALTH INC |
| ENALAPRIL | 02442957 | 2 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| ENALAPRIL | 02442965 | 4 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| ENALAPRIL | 02442973 | 8 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| ENALAPRIL | 02442981 | 16 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| JAMP ENALAPRIL | 02474786 | 2.5 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP ENALAPRIL | 02474794 | 5 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP ENALAPRIL | 02474808 | 10 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP ENALAPRIL | 02474816 | 20 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MAR-ENALAPRIL | 02444771 | 10 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-ENALAPRIL | 02444798 | 20 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-ENALAPRIL | 02459450 | 2.5 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| MAR-ENALAPRIL | 02459469 | 5 MG | TABLET · ORAL | MARCAN PHARMACEUTICALS INC |
| NRA-ENALAPRIL | 02565285 | 2.5 MG | TABLET · ORAL | NORA PHARMA INC |
14 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ENALAPRIL 1 MG/ML ORAL SOLN | $0.7946 | per ML | 23 Sep 2026 |
| US NADAC | ENALAPRIL MALEATE 10 MG TAB | $0.06635 | per EA | 23 Sep 2026 |
| US NADAC | ENALAPRIL MALEATE 2.5 MG TAB | $0.06251 | per EA | 23 Sep 2026 |
| US NADAC | ENALAPRIL MALEATE 20 MG TAB | $0.09526 | per EA | 23 Sep 2026 |
| US NADAC | ENALAPRIL MALEATE 5 MG TABLET | $0.0724 | per EA | 23 Sep 2026 |
| US NADAC | EPANED 1 MG/ML ORAL SOLUTION | $4.47849 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Enalapril 10mg tablets | £0.97 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Enalapril 2.5mg tablets | £5.78 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Enalapril 20mg tablets | £1.07 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Enalapril 250microgram orodispersible tablets sugar free | £34.25 | 50 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Enalapril 5mg tablets | £1.11 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Enalapril 5mg/5ml oral solution sugar free | £254.21 | 150 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.3. Antihypertensive medicines · core
Essential hypertension
Oral > Liquid: 1 mg per mL (as hydrogen maleate) (EMLc) | Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate) - 12.4. Medicines used in heart failure · core
Heart failure
Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)
Safety signals and safety-related labeling changes
- US FDA 20 Aug 2020 VASERETIC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions - US FDA 28 Jul 2017 EPANED — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Drug Interactions - US FDA 28 Jul 2017 EPANED KIT — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Jul 2017 VASOTEC — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions
Combinations containing Enalapril
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.